Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis

Abstract

Rationale:The association between intracranial hypertension (ICH) and ulcerative colitis (UC) is rare. We report the unusual case of a male patient with UC and ICH in whom both conditions resolved with mesalazine therapy.Patient concerns:A 48-year-old Caucasian man presented to our department in June 2016 for decreased vision, transient visual obscuration, pulsatile tinnitus and headaches of 7 months duration. Bilateral optic disc swelling was found at fundus examination. Brain MRI excluded any brain tumor and lumbar puncture showed cerebrospinal fluid (CSF) opening pressure of 26 cm of water with normal CSF contents.Diagnoses:Idiopathic ICH was suspected.Interventions:The patient was managed with oral acetazolamide. Headaches initially improved but the dosage could not be decreased under 750 mg a day without recurrence of the symptoms. Extensive review of systems showed that the patient had active UC. He was given oral mesalazine, 2000 mg a day.Outcomes:The symptoms of UC and ICH quickly resolved. Acetazolamide was progressively tapered over the course of the 9 subsequent months and the patient did not show any worsening of his symptoms or papilledema.Lessons:UC should be added to the list of disorders associated with ICH. In case of atypical ICH with drug dependency, investigations should seek for UC. Treating efficiently UC with mesalazine may improve ICH, suggesting an underlying inflammatory process.

Diagnosis of idiopathic intracranial hypertension - the importance of excluding secondary causes: A systematic review

“…Seventeen publications referred to antibiotics and antiviral medications (8–24), 10 referred to vitamin A and its derivatives (25–34), and eight to hormonal treatment (35–42). We found three additional publications referring to medication used for gastrointestinal diseases (43–45), two referred to psychotropic agents (46,47), two to immunosuppressive treatments (48,49) and one to the consumption of herbs (50).…”